The Cancer Education Program ofthe MSM/TU/UAB CCC Partnership seeks to introduce minority students at the undergraduate level to cancer research, including research on cancer disparities, through training, mentoring, and coursework. Its goal is to increase the number of minority scientists directing funded cancer research by facilitating the entry of more TU undergraduates into career paths that lead to cancer research. Two major efforts ofthe Program are: 1) Cancer Partnership Internships that will provide extensive training and mentoring to a small group of selected undergraduates, and 2) a new Health Disparities course that advances undergraduate and graduate students and other future health professionals and researchers. The TU juniors selected as Cancer Partnership Interns on the basis of potential for research success participate in two years of special activities that include a cancer research internship at a Partnership institution (UAB or MSM), presentation of research results, attendance at a national cancer research meeting, a Cancer Journal Club, a hands-on health disparities project, preparation for the GRE/MCAT, and structured mentoring for the transition to graduate study. The Health Disparities course, with emphasis on cancer and bioethics, is being offered at TU with review, recommendations, and guest lecturing by UAB and MSM investigators. The course is required for Cancer Partnership interns, but is open to other students. The purpose ofthe course is to motivate and equip students to pursue careers that address cancer and other health disparities by expanding their knowledge of data, issues, and research strategies that relate to disparities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA118948-09
Application #
8936036
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (O1))
Program Officer
Ogunbiyi, Peter
Project Start
2005-09-30
Project End
2016-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
$5,566
Indirect Cost
$1,737
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Luo, Yanzhuo; Li, Bingjin; Zhang, Guangxin et al. (2018) Integrated Oncogenomic Profiling of Copy Numbers and Gene Expression in Lung Adenocarcinomas without EGFR Mutations or ALK Fusion. J Cancer 9:1096-1105
Wang, Chiung-Min; Yang, William H; Liu, Runhua et al. (2018) FOXP3 Activates SUMO-Conjugating UBC9 Gene in MCF7 Breast Cancer Cells. Int J Mol Sci 19:
Moore, Justin Xavier; Royston, Kendra J; Langston, Marvin E et al. (2018) Mapping hot spots of breast cancer mortality in the United States: place matters for Blacks and Hispanics. Cancer Causes Control :
Akinyemiju, Tomi; Moore, Justin Xavier; Pisu, Maria et al. (2018) A Prospective Study of Obesity, Metabolic Health, and Cancer Mortality. Obesity (Silver Spring) 26:193-201
Akinyemiju, Tomi; Moore, Justin Xavier; Judd, Suzanne E et al. (2018) Pre-diagnostic biomarkers of metabolic dysregulation and cancer mortality. Oncotarget 9:16099-16109
Piyathilake, Chandrika J; Badiga, Suguna; Borak, Samuel G et al. (2017) A higher degree of expression of DNA methyl transferase 1 in cervical cancer is associated with poor survival outcome. Int J Womens Health 9:413-420
Williams, Samuel K; Braxton, Joanne M; Gosdin, Melissa et al. (2017) Evidence-Based Care for the Elderly: Uses of ""the Grandmother Principle"". J Health Care Poor Underserved 28:7
Gao, Song; Wang, Yicun; Wang, Meng et al. (2017) MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer. Oncotarget 8:41451-41464
Jia, Xu; Shanmugam, Chandrakumar; Paluri, Ravi K et al. (2017) Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget 8:20198-20212
Zhang, Yifan; Li, Bingjin; Zhang, Xingyi et al. (2017) CD24 is a genetic modifier for risk and progression of prostate cancer. Mol Carcinog 56:641-650

Showing the most recent 10 out of 193 publications